What is Drugs Made In America Acquisition Corp.'s (DMAA) StockRank?

MoatMap's StockRank for Drugs Made In America Acquisition Corp. (DMAA) is 16/100, with a Strong Sell signal. This is a composite score combining Quality (21), Value (21), and Momentum (53) factor ranks across MoatMap's universe of 25,000+ stocks.

Does Drugs Made In America Acquisition Corp. have an economic moat?

Drugs Made In America Acquisition Corp. (DMAA) has a Quality factor score of 21/100. The Quality factor combines ROIC, Piotroski F-Score, and leverage: the financial fingerprints of a durable competitive advantage. A Quality score above 70 typically indicates a company with the financial characteristics of a moated business.

Is Drugs Made In America Acquisition Corp. a buy, hold, or sell?

MoatMap's current signal for Drugs Made In America Acquisition Corp. (DMAA) is Strong Sell, based on a StockRank of 16/100. Signals are derived mechanically from the StockRank composite and should be one input among many; combine with your own thesis on management, competitive position, and valuation.

What sector is Drugs Made In America Acquisition Corp. in?

Drugs Made In America Acquisition Corp. (DMAA) operates in the Financial Services sector, specifically the Shell Companies industry (United States).

DMAA

Strong SellHot Air

Drugs Made In America Acquisition Corp. · Financial Services · United States · $261M · Avg Vol: $361K/d

Hot Air: Rising on momentum alone: weak business, rich price.

StockRank

Get insider-trade alerts

Quality

Value

Momentum

P/E (TTM)

60.2x

peers 12.6x

ROE

2.6%

peers 9.6%

D/E

—

peers 0.3x

Dividend %

—

trailing yield

Director trades · 180d

None →

Buybacks · 180d

None →

ABOUT DRUGS MADE IN AMERICA ACQUISITION CORP.

Read

Drugs Made In America Acquisition Corp. is a special purpose acquisition company (SPAC) formed for the purpose of effecting a merger, capital stock exchange, asset acquisition, stock purchase, reorganization, or similar business combination. The company currently possesses no active business operations, acting solely as a vehicle to acquire a private operating company. It represents an investment opportunity tied to the successful identification and execution of a de-SPAC transaction, likely focused on the pharmaceutical or biotechnology sector.

FINANCIAL SUMMARY (USD)

Year	2024	2025	TTM
Revenue	—	0	—
EPS	—	0.19	0.18
Shares	30.5M	33.7M	—
Debt	0.7M	—	0.3M
Equity	-0.2M	232.6M	—
Op CF	—	-0.5M	-0.5M
Inv CF	—	-231.2M	—
Fin CF	—	231.7M	—

Loading 1Y...

PRICE (1Y)+1.3%

SMA 50SMA 200

$10.84

RSI (14)

90.9

52W High

$10.85

From 52W High

1.0%

SCORE BREAKDOWN

Quality

ROIC

-1.1%8.7

ROE

2.6%25.0

GP/Assets

—N/A

Op. Margin

0.0%14.1

FCF/Assets

—N/A

Piotroski

215.7

Int. Cover

—N/A

D/E Ratio

—N/A

Current Ratio

0.02x1.7

Value

P/E (TTM)

60.2x4.3

EV/EBITDA

—N/A

P/FCF

—N/A

P/B

-35.5x25.0

P/S

—N/A

Div Yield

—N/A

Momentum

52W High %

100%98.5

RS 6M

-13%33.4

SMA 50/200

1.02x45.1

EPS Rev 4W

—N/A

EPS Rev 12W

—N/A

EPS Improve

—N/A

Q Growth

-25%13.9

FUNDAMENTALS

Market Cap

$261M

P/E (Forward)

—

Gross Margin

—

SECTOR PEERS

Closest peers in Financial Services, ranked by industry match, size, and score similarity. Cross-listings of DMAA are excluded.

Ticker	Company	Mkt Cap	StockRank	Signal
DMAA	Drugs Made In America Acquisition Corp.(you)	$261M	16	Strong Sell
CUB	Lionheart Holdings	$285M	16	Strong Sell
OACC	Oaktree Acquisition Corp. III Life Sciences	$264M	18	Strong Sell
MCGA	Yorkville Acquisition Corp.	$244M	15	Strong Sell
SBXD	SilverBox Corp IV	$276M	13	Strong Sell
ATII	Archimedes Tech SPAC Partners II Co.	$316M	16	Strong Sell
JACS	Jackson Acquisition Company II	$318M	16	Strong Sell
NTWO	Newbury Street II Acquisition Corp	$267M	11	Strong Sell
BLRK	Bluerock Acquisition Corp.	$232M	13	Strong Sell
MACI	Melar Acquisition Corp. I	$238M	19	Strong Sell

Peer medians: ROE 9.6% · P/E 12.6x · Gross margin 100.0%

Company Deep Dive

Business segments breakdown, earnings transcript analysis, management credibility scoring, competitive landscape, and scenario modelling.

Request Deep Dive(50 Feathers)

Drugs Made In America Acquisition Corp. (DMAA): Stock Score Summary

Drugs Made In America Acquisition Corp. (DMAA) has a MoatMap StockRank of 16/100 based on Quality (21/100), Value (21/100), and Momentum (53/100) factor scores. The current signal is STRONG SELL.

Key Financial Metrics

Price	$10.84
Market Cap	$261M
P/E (TTM)	60.22
Price/Book	-35.54
Return on Equity	2.6%
Return on Invested Capital	-1.1%
Operating Margin	0.0%

Drugs Made In America Acquisition Corp. operates in the Shell Companies industry, part of the Financial Services sector (United States).

Frequently Asked Questions

What is Drugs Made In America Acquisition Corp.’s (DMAA) StockRank?: MoatMap’s StockRank for Drugs Made In America Acquisition Corp. (DMAA) is 16/100, with a Strong Sell signal. It is a composite of Quality (21), Value (21), and Momentum (53) factor ranks across MoatMap’s universe of 25,000+ stocks.
Does Drugs Made In America Acquisition Corp. have an economic moat?: Drugs Made In America Acquisition Corp. (DMAA) has a Quality factor score of 21/100. The Quality factor combines ROIC, Piotroski F-Score, and leverage: the financial fingerprints of a durable competitive advantage. A Quality score above 70 typically indicates a company with the characteristics of a moated business.
Is Drugs Made In America Acquisition Corp. a buy, hold, or sell?: MoatMap’s current signal for Drugs Made In America Acquisition Corp. (DMAA) is Strong Sell, based on a StockRank of 16/100. Signals are derived mechanically from the StockRank composite and should be one input among many; combine with your own thesis on management, competitive position, and valuation.
What sector is Drugs Made In America Acquisition Corp. in?: Drugs Made In America Acquisition Corp. (DMAA) operates in the Financial Services sector, specifically the Shell Companies industry (United States).